Quanterix has developed an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina.
Simoa® Assay Kits
Ready-to-use Simoa® kits contain all the reagents necessary to run your assay on the HD-1, HD-X , SR-X or SP-X platforms. Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology.
Quanterix Simoa® Technology detects femtogram-level biomarkers for early disease detection and management in neurology, oncology, immunology, cardiology, and infectious diseases.
The Homebrew Process
For Custom Immunoassay Development In a matter of days, you can develop custom immunoassays with ultrasensitivity. The Quanterix Homebrew Assay Development Kit and your proprietary reagents work together for rapid Simoa® assay prototyping with improved biomarker detection and ease-of-use compared to standard ELISA.